Chikungunya Vaccine Development May Rely On Immunologic Biomarkers Instead Of Traditional Trials

As the mosquito-borne chikungunya virus spreads into temperate regions worldwide, US FDA convenes advisory committee for an open discussion on development of vaccines.

More from US FDA Performance Tracker

More from Regulatory Trackers